PUBLICATIONS - Here you will find, in chronological order, the pubblications of Andrea Alimonti. - ALIMONTI LABORATORY

Alimonti Lab
Alimonti Lab
Alimonti Lab
Go to content
_____
 
“Literature, like all the arts, is the
confession that life is not enough
2018
 

 
1)Arianna Calcinotto, Clarissa Spataro, Elena Zagato, Diletta Di Mitri, Veronica Gil, Mateus Crespo, Gaston De Bernardis, Marco Losa, Michela Mirenda, Emiliano Pasquini, Andrea Rinaldi, Semini Sumanasuriya, Maryou B. Lambros, Antje Neeb, Roberta Lucianò, Carlo A. Bravi, Daniel Nava-Rodrigues, David Dolling, Tommaso Prayer-Galetti, Ana Ferreira, Alberto Briganti, Antonio Esposito, Simon Barry, Wei Yuan, Adam Sharp, Johann de Bono & Andrea Alimonti. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer, Nature volume 559, pages 363–369 (7 June 2018). https://doi.org/10.1038/s41586-018-0266-0



2) Jingjing Chen, Ilaria Guccini, Diletta Di Mitri, Daniela Brina, Ajinkya Revandkar, Emiliano Pasquini, Abdullah Alajati, Sandra Pinton, Gianluca Civenni, Carlo Catapano, Jacopo Sgrignani, Andrea Cavalli, Rocco D'Antuono, John M. Asara, Andrea Morandi, Paola Chiarugi, Ionica Masgras, Andrea Rasola, Ramon Garcia-Escudero, Nicolas Delaleu, Andrea Rinaldi, Francesco Bertoni, Arkaitz Carracedo  & Andrea Alimonti. Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nature Genetics 2018, Jen 15, doi:10.1038/s41588-017-0026-3
 

2017
 

 
2) Amaia Zabala-Letona1, Amaia Arruabarrena-Aristorena, Natalia Martín-Martín, Sonia Fernandez-Ruiz, James D. Sutherland, Michelle Clasquin, Julen Tomas-Cortazar, Jose Jimenez, Ines Torres, Phong Quang, Pilar Ximenez-Embun, Ruzica Bago, Aitziber Ugalde-Olano, Ana Loizaga-Iriarte, Isabel Lacasa-Viscasillas, Miguel Unda, Verónica Torrano, Diana Cabrera, Sebastiaan M. van Liempd, Ylenia Cendon, Elena Castro, Stuart Murray, Ajinkya Revandkar, Andrea Alimonti, Yinan Zhang, Amelia Barnett, Gina Lein, David Pirman, Ana R. Cortazar, Leire Arrea, Ludmila Prudkin, Ianire Astobiza, Lorea Valcarcel-Jimenez, Patricia  Zuñiga-García, Itziar Fernandez-Dominguez, Marco Piva, Alfredo Caro-Maldonado, Pilar Sánchez-Mosquera, Mireia Castillo-Martín, Violeta Serra, Naiara Beraza, Antonio Gentilella, George Thomas, Mikel Azkargorta, Felix Elortza, Rosa Farràs, David Olmos, Alejo Efeyan, Juan Anguita, Javier Muñoz, Juan M. Falcón-Pérez, Rosa Barrio, Teresa Macarulla, Jose M. Mato, Maria L. Martinez-Chantar, Carlos Cordon-Cardo, Ana M. Aransay, Kevin Marks, Jose Baselga, Josep Tabernero, Paolo Nuciforo, Brendan D.  Manning, Katya Marjon, Arkaitz Carracedo. mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature. 2017 Jul 6;547(7661):109-113
 

 
3)  Arinna Calcinotto and Andrea Alimonti. Aging tumor cells to treat cancer: “Pro-senescence” therapy for cancer. Swiss Med Wkly 2017 Jan 19;147:w14367. doi: smw.2017.14367
 

 
2016
 

 
4) Ajinkya Revandkar, Maria Luna Perciato, Alberto Toso, Abdullah Alajati, Jingjing Chen, Hermeto Gerber, Mitko Dimitrov, Andrea Rinaldi, Nicolas Delaleu, Emiliano Pasquini, Rocco D’Antuono, Sandra Pinton, Marco Losa, Alberto Arribas, Patrick Fraering, Francesco Bertoni, Alain Nepveu, & Andrea Alimonti. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.      Nat Commun. 2016 Dec 12;7:13719. doi: 10.1038/ncomms13719
 

 
5) Matic I, Revandkar A, Chen J, Bisio A, Dall'Acqua S, Cocetta V, Brun P, Mancino G, Milanese M, Mattei M, Montopoli M, Alimonti A. Identification of Salvia haenkei as gerosuppressant agent by using an integrated senescence-screening assay. Aging (Albany NY). 2016 Dec 1;8(12):3223-3240. doi: 10.18632/aging.101076.
 

 
6) Di Mitri D, Alimonti A. Non-Cell-Autonomous Regulation of Cellular Senescence in Cancer. Trends Cell Biol. 2016 Nov 9. pii: S0962-8924(15)00192-0. doi: 10.1016/j.tcb.2015.10.005
 

 
2015
 

 
7) Madhuri Kalathur, Alberto Toso, Jingjing Chen, Ajinkya Revandkar, Claudia Danzer-Baltzer, Ilaria Guccini, Abdullah Alajati, Manuela Sarti, Sandra Pinton, Lara Brambilla, Diletta Dimitri, Giuseppina Carbone, Ramon Garcia-Escudero, Alessandro Padova, Letizia Magnoni, Laura Maccari, Mr. Federico Malusa, Ravi Kiran Kalathur, Lorenzo Pinna, Maria Ruzzene, Giorgio Cozza, Carlo Catapano, Ian Frew & Andrea Alimonti. A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. Nat Commun. 2015 Jun 18;6:7227.
 

 
8) Diletta Di Mitri, Alberto Toso & Andrea Alimonti. Myeloid-derived -suppressor cells in prostate cancer therapy. Clin Cancer Res 2015, May 12.
 

 
9) Diletta Di Mitri, Alberto Toso & Andrea Alimonti. Tumour infiltrating myeloid cells drive senescence evasion and chemoresistance in cancer. Oncoimmunology 2015 Jun 3;4(9):e988473
 

 
10) Alberto Toso, Diletta Di Mitri & Andrea Alimonti. Enhancing chemotherapy efficacy by reprogramming the senescence-associated secretory phenotype of prostate tumors. “A way to reactivate the anti-tumor immunity". Oncoimmunology. 2015 Jan 22;4(3):e994380.
 
11) Abullah Alajati, Ilaria Guccini and Andrea Alimonti. Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. Cell Rep. 2015 Apr 15.
 

 
2014
 

 
12) Zovko A, Viktorsson K, Hååg P, Kovalerchick D, Färnegårdh K, Alimonti A, Ilan M, Carmeli S, Lewensohn R. Marine sponge Cribrochalina vasculum compounds activate intrinsic apoptotic signaling and inhibit growth factor signaling cascades in non-small cell lung carcinoma. Mol Cancer Ther. 2014 Dec;13(12):2941-54. doi: 10.1158/1535-7163.MCT-14-0329. Epub 2014 Oct 15.
 

 
13) Diletta Di Mitri, Alberto Toso, Jing Jing Chen, Manuela Sarti, Sandra Pinton, Tanja Rezzonico Jost, Rocco D’Antuono, Erica Montani, Ramon Garcia-Escudero, Ilaria Guccini, Sabela Da Silva, Manuel Collado, Mario Eisenberger, Zhe Zheng, Carlo Catapano, Fabio Grassi & Andrea Alimonti. Tumour infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature 2014 Aug 24. doi: 10.1038/nature13638.
 

 
14) Alberto Toso, Ajinkya Revandkar, Diletta Di Mitri, Ilaria Guccini, Michele Proietti, Manuela Sarti, Sandra Pinton, Jiangwen Zhang, Madhuri Kalathur, Gianluca Civenni, David Jarrossay, Camilla Marini, Eugenio Scanziani, Fabio Grassi, Pier Paolo Pandolfi, Carlo V. Catapano and Andrea Alimonti. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Reports 9, 1–15, October 9, 2014 12.       
 

 
1) Patents and licenses
 
EP 2762131 A1: Use of Salvia Haenkei extracts in compositions for antisenescence
 
2) Oral contributions to international conferences

 
Invited Lectures:
 

 
2017 AACR Prostate meeting, Orlando, USA
 
Alimonti A: Targeting tumor-infiltrating myeloid cells for cancer therapy
 
2017 MAP_meeting, Zurich, Switzerland
 
Alimonti A: Targeting PTEN null tumors for cancer therapy
 
2017 ESMO_meeting, Madrid, Spain
 
Alimonti A: Immune regulation of prostate cancer
 
2017 BIDMC_Harvard Medical School_Senescence & Aging Symposium
 
Alimonti A: Targeting the cancer genome and the tumour immune response for pro-senescence therapy
 
2016 NCRI Liverpool, UK
 
Alimonti A: Targeting tumor-infiltrating myeloid cells for cancer therapy
 
2016 ISREC-SCCL Symposium 2016, Lausanne, Switzerland
 
Alimonti A: Macrophages reprogramming for "pro-senescence" therapy for cancer,
 
2016 Movember meeting on prostate cancer, London, UK
 
Alimonti A: Role of MDSCs in prostate cancer
 
2016 The Function of Tumor Microenvironment in Cancer Progression, AACR, San Diego
 
Alimonti A: Targeting the tumor microenviroment for prostate cancer therapy
 
2016 Lola and John Grace Distinguished Lectures in Cancer Research, ISREC, Lausanne
 
Alimonti A: Targeting the tumor microenviroment for prostate cancer therapy
 
2016 INT Milan, Italy
 
Alimonti A: Dual Targeting of senescence and the tumor immunity for prostate cancer therapy
 
2015 San Raffaele, Milan, Italy
 
Alimonti A: Non-cell autonomus regulation of senecence in cancer and cancer therapy
 
2015 IBSA Workshop in Cancer and Immunology, Switzerland (organizer)
 
Alimonti A: Immune senescence therapy for Cancer
 
2015 ICSA meeting, Santiago de Compostela (scheduled)
 
Alimonti A: Pten loss induced cellular senescence
 
2015, AIMAR, Pescara Ialia (scheduled)
 
Alimonti A: Role of myeloid cells in chemotherapy resistance (Scheduled)
 
2015, AFI (Farmindustria) meeting, Rimini, Italia (Scheduled)
 
Alimonti A: Immunotherapy in prostate cancer
 
2015, Edinburgh Cancer Research Centre(scheduled)
 
Alimonti A: Immune senescence therapy for cancer
 
2015, MRC, London (scheduled)
 
Alimonti A:Targeting senescence for cancer therapy
 
2015.EMBO meeting, Europhosphatase 2015 (scheduled)
 
Alimonti A: Identification of a novel phosphatase network that promotes tumor immune evasion
 
2015. IDIBELL, Barcellona (scheduled)
 
Alimonti A:Targeting senescence for cancer therapy
 
2014. Novartis, Basel meeting
 
Alimonti A: Immune senescence therapy for Cancer
 
2014 University of Padova¨, Italy
 
Alimonti A : Pro-senescence therapy for Cancer
 
2014. EMBO meeting, Translational advances in cancer cell signaling and metabolism, Bilbao, Spain.
 
Alimonti A: Targeting the tumor immune system for pro-senescence therapy for cancer
 
2014 1th ESMO Symposium on Signaling Pathways
 
Alimonti A: PTEN
 
2013 Cologne University HospitalOnco-seminar series
 
Alimonti A:”Pro-senescence” therapy for cancer
 
2013 Sino Swiss Symposium, Beijing, China
 
Alimonti A: Reprogramming the senescence associated tumor secretory phenotype for cancer therapy
 
2013 Barts and the London School of Medicine
 
Alimonti A: Reprogramming the senescence associated tumor secretory phenotype for cancer therapy
 
2013 Centre Hospitalier Universitaire Vaudois  Lausanne, Switzerland
 
Alimonti A: Immune-senescence therapy for cancer
 
2013 UNIRAD meeting, Paris, France
 
Alimonti A: Targeting mTOR for cancer therapy
 
2012 Cicbiogune, Bilbao, Spain
 
Alimonti A: Immune-senescence therapy for cancer
 
2012 Stepping Stone Symposium, ETH Zurich, Switzerland
 
Alimonti A: PTEN levels in tumor suppression and cancer therapy
 
2012 4th IMPAKT Breast Cancer Conference, Brussels, Belgium
 
Alimonti A: PTEN loss a master regulator?
 
2011 TAT 2011 International Symposium on targeted anticancer therapies, Paris, France
 Alimonti A: PTEN loss induced cellular senescence for "Pro-senescence" therapy for cancer.
Read Privacy Policy - Alimonti Laboratoy ® 2018, Credits by The Art Of Giulio Perez
PARTNERS
Alimonti Lab
Alimonti Lab
Alimonti Lab
Back to content